GEN Exclusives

More »

GEN News Highlights

More »
Jun 23, 2008

EyeCyte Obtains $3M from Pfizer through Series A Round

  • EyeCyte secured a $3 million series A financing through an agreement with Pfizer. The backing will reportedly support the company into 2010. EyeCyte focuses on stem/progenitor cell-based ophthalmology R&D.

    According to this investment, Pfizer will become EyeCyte’s sole pharmaceutical partner and have an advisory and board role. Pfizer will also have right of first refusal for a buy-out of EyeCyte or its technologies.

    “We are very pleased with the terms of our collaboration and believe that Pfizer shares our goal of building a premier ophthalmology research and development organization with an emphasis on stem/progenitor cell based therapies,” remarks Mohammad A. El-Kalay, Ph.D., president and CEO, EyeCyte.


Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Ebola Vaccines

When do you think an Ebola vaccine will be available for the general public?